PBIRx has a New Look!

We’re still the same company, but we have updated our materials to better communicate who we are and how our products and services support your quest for better and more affordable pharmacy benefit plans!   

Data and creative cost savings solutions require “very specialized thinking” and we are proud and fortunate of the team we employ with their varied expertise, intelligence, and longevity in the industry and with PBIRx.

Bold letter forms represent our confidence and tenacity in everything we do.

The Brain represents our capacity to combine our comprehensive and analytical understanding of pharmacy benefits.  Our recommendations are based on right-brain/left-brain thinking.

The Tablets represent our focus on medications, formularies and clinical recommendation that provide better member benefit and health outcomes.

The Gradient Colors represent the dynamic, fast changing healthcare landscape.

PBI stands for Pharmacy Benefit Intelligence, which is what we live and what we deliver.

Our focus continues to be on our clients.  We evaluate current drug usage and spend, claim by claim, and then model and present alternative opportunities customized for each client which can yield measurable plan and member savings enhancing benefits while delivering optimum health outcomes.

PBIRx® has been exclusively providing intelligent solutions to clients in the management of pharmacy benefit costs since 1993. With a staff that includes IT personnel, actuaries, financial analysts, clinical pharmacists, attorneys, HIPAA Compliance Officers and many more experts, PBIRx’s mission is to create optimal healthcare outcomes while minimizing overall healthcare costs. For more information, please visit www.pbirx.com or call (888) 797-2479.

Two New Drugs for Multiple Sclerosis

Two New Drugs for Multiple Sclerosis

The FDA has recently approved two new oral drugs for the treatment of Multiple Sclerosis (MS).

Over the last few years, three oral drugs for MS have become available: Gilenya came to the US market in 2010; Aubagio was released in 2012; and Tecfidera in 2013. Prior to that, all therapies were injectables.

Mavenclad (cladribine), an oral form of an older drug, given intravenously for certain types of leukemia, was FDA approved for the treatment of relapsing forms of MS  including active secondary progressive disease in adults. As a result of its safety profile, it’s generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS. Treatment with Mavenclad may increase the risk of malignancy.

Uniquely, Mavenclad is only administered twice over four or five days, for two treatment courses which are spaced about a year apart. After that, the patient doesn’t receive any medication for at least two years. The dose is weight-based; the total annual cost for an average 80kg person (176 lbs) is $127,900. Though it’s given much less frequently than any of the other currently available monthly oral medications, it is more expensive per month ($10,661).

Mayzent (siponimod), was approved for the same indication. The dose is also unusual: 0.25 mg once daily on Days 1 and 2; 0.5 mg once daily on Day 3; 0.75 mg once daily on Day 4; 1.25 mg once daily on Day 5. The maintenance dose is 2 mg once daily beginning on Day 6. The monthly cost is $8,729.

Only time will tell how these two new drugs will perform in the Multiple Sclerosis landscape.

PBIRx has been exclusively providing intelligent solutions to clients in the management of pharmacy benefit costs since 1993. With a staff that includes IT personnel, actuaries, financial analysts, clinical pharmacists, attorneys, HIPAA Compliance Officers and many more experts, PBIRx’s mission is to create optimal healthcare outcomes while minimizing overall healthcare costs. For more information, please visit www.pbirx.com or call (888) 797-2479.